- Home
- Publications
- Publication Search
- Publication Details
Title
Investigational drugs for head and neck cancer
Authors
Keywords
-
Journal
EXPERT OPINION ON INVESTIGATIONAL DRUGS
Volume 25, Issue 7, Pages 797-810
Publisher
Informa UK Limited
Online
2016-04-08
DOI
10.1080/13543784.2016.1175435
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Innovative perspectives of immunotherapy in head and neck cancer. From relevant scientific rationale to effective clinical practice
- (2016) Y. Lalami et al. CANCER TREATMENT REVIEWS
- Phase II trial of everolimus and erlotinib in patients with platinum-resistant recurrent and/or metastatic head and neck squamous cell carcinoma
- (2015) E. Massarelli et al. ANNALS OF ONCOLOGY
- Phase I and biomarker study of OPB-51602, a novel signal transducer and activator of transcription (STAT) 3 inhibitor, in patients with refractory solid malignancies
- (2015) A. L. Wong et al. ANNALS OF ONCOLOGY
- Tivantinib (ARQ-197) exhibits anti-tumor activity with down-regulation of FAK in oral squamous cell carcinoma
- (2015) Wei-Hong Xi et al. BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS
- Evolutionary Action Score of TP53 Coding Variants Is Predictive of Platinum Response in Head and Neck Cancer Patients
- (2015) A. A. Osman et al. CANCER RESEARCH
- Wee-1 Kinase Inhibition Sensitizes High-Risk HPV+ HNSCC to Apoptosis Accompanied by Downregulation of MCl-1 and XIAP Antiapoptotic Proteins
- (2015) N. Tanaka et al. CLINICAL CANCER RESEARCH
- MEK Inhibitor PD-0325901 Overcomes Resistance to PI3K/mTOR Inhibitor PF-5212384 and Potentiates Antitumor Effects in Human Head and Neck Squamous Cell Carcinoma
- (2015) S. Mohan et al. CLINICAL CANCER RESEARCH
- Results of a phase 1 trial combining ridaforolimus and MK-0752 in patients with advanced solid tumours
- (2015) S.A. Piha-Paul et al. EUROPEAN JOURNAL OF CANCER
- MEK Inhibitor PD-0325901 Overcomes Resistance to CK2 Inhibitor CX-4945 and Exhibits Anti-Tumor Activity in Head and Neck Cancer
- (2015) Yansong Bian et al. International Journal of Biological Sciences
- Antitumor activity and safety of pembrolizumab in patients (pts) with advanced squamous cell carcinoma of the head and neck (SCCHN): Preliminary results from KEYNOTE-012 expansion cohort.
- (2015) Tanguy Y. Seiwert et al. JOURNAL OF CLINICAL ONCOLOGY
- Genetic Landscape of Human Papillomavirus–Associated Head and Neck Cancer and Comparison to Tobacco-Related Tumors
- (2015) D. Neil Hayes et al. JOURNAL OF CLINICAL ONCOLOGY
- Phase I Study of Single-Agent AZD1775 (MK-1775), a Wee1 Kinase Inhibitor, in Patients With Refractory Solid Tumors
- (2015) Khanh Do et al. JOURNAL OF CLINICAL ONCOLOGY
- Palbociclib in Hormone-Receptor–Positive Advanced Breast Cancer
- (2015) Nicholas C. Turner et al. NEW ENGLAND JOURNAL OF MEDICINE
- The opposing roles of NOTCH signalling in head and neck cancer: a mini review
- (2015) LF Yap et al. ORAL DISEASES
- A randomized, phase 2 trial of docetaxel with or without PX-866, an irreversible oral phosphatidylinositol 3-kinase inhibitor, in patients with relapsed or metastatic head and neck squamous cell cancer
- (2015) Antonio Jimeno et al. ORAL ONCOLOGY
- A first-in-human study of AMG 208, an oral MET inhibitor, in adult patients with advanced solid tumors
- (2015) David S. Hong et al. Oncotarget
- The novel proteasome inhibitor carfilzomib activates and enhances extrinsic apoptosis involving stabilization of death receptor 5
- (2015) Bo Han et al. Oncotarget
- Anti-Tumor Immunity in Head and Neck Cancer: Understanding the Evidence, How Tumors Escape and Immunotherapeutic Approaches
- (2015) Clint Allen et al. Cancers
- The current and future impact of human papillomavirus on treatment of squamous cell carcinoma of the head and neck
- (2014) A. Psyrri et al. ANNALS OF ONCOLOGY
- A randomized, phase II trial of cetuximab with or without PX-866, an irreversible oral phosphatidylinositol 3-kinase inhibitor, in patients with relapsed or metastatic head and neck squamous cell cancer
- (2014) A. Jimeno et al. ANNALS OF ONCOLOGY
- TEMHEAD: a single-arm multicentre phase II study of temsirolimus in platin- and cetuximab refractory recurrent and/or metastatic squamous cell carcinoma of the head and neck (SCCHN) of the German SCCHN Group (AIO)†
- (2014) V. Grünwald et al. ANNALS OF ONCOLOGY
- A multicenter phase II study of everolimus in patients with progressive unresectable adenoid cystic carcinoma
- (2014) Dong-Wan Kim et al. BMC CANCER
- Phase 1 and pharmacokinetic study of everolimus in combination with cetuximab and carboplatin for recurrent/metastatic squamous cell carcinoma of the head and neck
- (2014) Nabil F. Saba et al. CANCER
- What is the best treatment for patients with human papillomavirus-positive and -negative oropharyngeal cancer?
- (2014) Damien Urban et al. CANCER
- Carfilzomib and oprozomib synergize with histone deacetylase inhibitors in head and neck squamous cell carcinoma models of acquired resistance to proteasome inhibitors
- (2014) Yan Zang et al. CANCER BIOLOGY & THERAPY
- Phase 1, open-label, dose-escalation, and pharmacokinetic study of STAT3 inhibitor OPB-31121 in subjects with advanced solid tumors
- (2014) Johanna C. Bendell et al. CANCER CHEMOTHERAPY AND PHARMACOLOGY
- Lenvatinib in combination with golvatinib overcomes hepatocyte growth factor pathway-induced resistance to vascular endothelial growth factor receptor inhibitor
- (2014) Takayuki Nakagawa et al. CANCER SCIENCE
- Phase I Study of Oral Rigosertib (ON 01910.Na), a Dual Inhibitor of the PI3K and Plk1 Pathways, in Adult Patients with Advanced Solid Malignancies
- (2014) D. W. Bowles et al. CLINICAL CANCER RESEARCH
- The prognostic value of cyclin D1 expression in head and neck squamous cell carcinoma
- (2014) Federico M. Gioacchini et al. EUROPEAN ARCHIVES OF OTO-RHINO-LARYNGOLOGY
- Early investigational drugs that target epidermal growth factor receptors for the treatment of head and neck cancer
- (2014) Gamze Ugurluer et al. EXPERT OPINION ON INVESTIGATIONAL DRUGS
- Combination of proteasome and class I HDAC inhibitors induces apoptosis of NPC cells through an HDAC6-independent ER stress-induced mechanism
- (2014) Kwai Fung Hui et al. INTERNATIONAL JOURNAL OF CANCER
- mTOR Co-Targeting in Cetuximab Resistance in Head and Neck Cancers Harboring PIK3CA and RAS Mutations
- (2014) Zhiyong Wang et al. JNCI-Journal of the National Cancer Institute
- Wee-1 Kinase Inhibition Overcomes Cisplatin Resistance Associated with High-Risk TP53 Mutations in Head and Neck Cancer through Mitotic Arrest Followed by Senescence
- (2014) A. A. Osman et al. MOLECULAR CANCER THERAPEUTICS
- A multicenter, phase II trial of everolimus in locally advanced or metastatic thyroid cancer of all histologic subtypes
- (2013) S. M. Lim et al. ANNALS OF ONCOLOGY
- Tumour response and safety of cetuximab in a window pre-operative study in patients with squamous cell carcinoma of the head and neck
- (2013) S. Schmitz et al. ANNALS OF ONCOLOGY
- Cancer statistics, 2013
- (2013) Rebecca Siegel et al. CA-A CANCER JOURNAL FOR CLINICIANS
- A phase 1 study of everolimus plus docetaxel plus cisplatin as induction chemotherapy for patients with locally and/or regionally advanced head and neck cancer
- (2013) Matthew G. Fury et al. CANCER
- Evidence for a Role of the PD-1:PD-L1 Pathway in Immune Resistance of HPV-Associated Head and Neck Squamous Cell Carcinoma
- (2013) S. Lyford-Pike et al. CANCER RESEARCH
- Alteration of cancer stem cell-like phenotype by histone deacetylase inhibitors in squamous cell carcinoma of the head and neck
- (2013) Kazuaki Chikamatsu et al. CANCER SCIENCE
- Targeted therapies for squamous cell carcinoma of the head and neck: Current knowledge and future directions
- (2013) Sandra Schmitz et al. CANCER TREATMENT REVIEWS
- A Phase 1 Study of Everolimus + Weekly Cisplatin + Intensity Modulated Radiation Therapy in Head-and-Neck Cancer
- (2013) Matthew G. Fury et al. INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS
- Whole exome sequencing of adenoid cystic carcinoma
- (2013) Philip J. Stephens et al. JOURNAL OF CLINICAL INVESTIGATION
- Cabozantinib in Progressive Medullary Thyroid Cancer
- (2013) Rossella Elisei et al. JOURNAL OF CLINICAL ONCOLOGY
- Use of Statins and the Risk of Death in Patients With Prostate Cancer
- (2013) Oriana Yu et al. JOURNAL OF CLINICAL ONCOLOGY
- Novel targets in HPV-negative head and neck cancer: overcoming resistance to EGFR inhibition
- (2013) Barbara Burtness et al. LANCET ONCOLOGY
- Bortezomib and SAHA Synergistically Induce ROS-Driven Caspase-Dependent Apoptosis of Nasopharyngeal Carcinoma and Block Replication of Epstein-Barr Virus
- (2013) K. F. Hui et al. MOLECULAR CANCER THERAPEUTICS
- Signatures of mutational processes in human cancer
- (2013) Ludmil B. Alexandrov et al. NATURE
- The mutational landscape of adenoid cystic carcinoma
- (2013) Allen S Ho et al. NATURE GENETICS
- Crizotinib versus Chemotherapy in Advanced ALK-Positive Lung Cancer
- (2013) Alice T. Shaw et al. NEW ENGLAND JOURNAL OF MEDICINE
- A phase II study of temsirolimus and erlotinib in patients with recurrent and/or metastatic, platinum-refractory head and neck squamous cell carcinoma
- (2013) Julie E. Bauman et al. ORAL ONCOLOGY
- Inhibition of Histone Deacetylase Impacts Cancer Stem Cells and Induces Epithelial-Mesenchyme Transition of Head and Neck Cancer
- (2013) Fernanda S. Giudice et al. PLoS One
- The novel HDAC inhibitor NDACI054 sensitizes human cancer cells to radiotherapy
- (2013) Stephanie Hehlgans et al. RADIOTHERAPY AND ONCOLOGY
- Frequent Mutation of the PI3K Pathway in Head and Neck Cancer Defines Predictive Biomarkers
- (2013) V. W. Y. Lui et al. Cancer Discovery
- Targeted next-generation sequencing of head and neck squamous cell carcinoma identifies novel genetic alterations in HPV+ and HPV- tumors
- (2013) Matthias Lechner et al. Genome Medicine
- The Molecular Crosstalk between the MET Receptor Tyrosine Kinase and the DNA Damage Response—Biological and Clinical Aspects
- (2013) Michaela Medová et al. Cancers
- The next generation proteasome inhibitors carfilzomib and oprozomib activate prosurvival autophagy via induction of the unfolded protein response and ATF4
- (2012) Yan Zang et al. Autophagy
- A phase I study of temsirolimus plus carboplatin plus paclitaxel for patients with recurrent or metastatic (R/M) head and neck squamous cell cancer (HNSCC)
- (2012) Matthew G. Fury et al. CANCER CHEMOTHERAPY AND PHARMACOLOGY
- Phase I/II Trial of Carboplatin and Paclitaxel Chemotherapy in Combination with Intravenous Oncolytic Reovirus in Patients with Advanced Malignancies
- (2012) E. M. Karapanagiotou et al. CLINICAL CANCER RESEARCH
- The histone deacetylase inhibitor trichostatin A reduces lysosomal pH and enhances cisplatin-induced apoptosis
- (2012) I. Eriksson et al. EXPERIMENTAL CELL RESEARCH
- Phase II 2-arm trial of the proteasome inhibitor, PS-341 (bortezomib) in combination with irinotecan or PS-341 alone followed by the addition of irinotecan at time of progression in patients with locally recurrent or metastatic squamous cell carcinoma of
- (2012) Jill Gilbert et al. HEAD AND NECK-JOURNAL FOR THE SCIENCES AND SPECIALTIES OF THE HEAD AND NECK
- Phase I Trial Using the Proteasome Inhibitor Bortezomib and Concurrent Chemoradiotherapy for Head-and-Neck Malignancies
- (2012) Gregory J. Kubicek et al. INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS
- Activity of the MEK inhibitor selumetinib (AZD6244; ARRY-142886) in nasopharyngeal cancer cell lines
- (2012) Brigette B. Y. Ma et al. INVESTIGATIONAL NEW DRUGS
- Targeting the Hepatocyte Growth Factor–cMET Axis in Cancer Therapy
- (2012) George R. Blumenschein et al. JOURNAL OF CLINICAL ONCOLOGY
- Phase II trial of the histone deacetylase inhibitor romidepsin in patients with recurrent/metastatic head and neck cancer
- (2012) Missak Haigentz et al. ORAL ONCOLOGY
- Effects of lapatinib monotherapy: results of a randomised phase II study in therapy-naive patients with locally advanced squamous cell carcinoma of the head and neck
- (2011) J M del Campo et al. BRITISH JOURNAL OF CANCER
- A phase 2 trial of bortezomib followed by the addition of doxorubicin at progression in patients with recurrent or metastatic adenoid cystic carcinoma of the head and neck
- (2011) Athanassios Argiris et al. CANCER
- ERK1/2 Regulation of CD44 Modulates Oral Cancer Aggressiveness
- (2011) N. P. Judd et al. CANCER RESEARCH
- Early Tumor Progression Associated with Enhanced EGFR Signaling with Bortezomib, Cetuximab, and Radiotherapy for Head and Neck Cancer
- (2011) A. Argiris et al. CLINICAL CANCER RESEARCH
- Histone deacetylase-1 and -2 expression in mobile tongue squamous cell carcinoma: associations with clinicopathological parameters and patients survival
- (2011) Stamatios Theocharis et al. JOURNAL OF ORAL PATHOLOGY & MEDICINE
- HDAC2 promotes cell migration/invasion abilities through HIF-1α stabilization in human oral squamous cell carcinoma
- (2011) Cheng-Chi Chang et al. JOURNAL OF ORAL PATHOLOGY & MEDICINE
- Inhibition of NOTCH3 signalling significantly enhances sensitivity to cisplatin in EBV-associated nasopharyngeal carcinoma
- (2011) Cheuk-Him Man et al. JOURNAL OF PATHOLOGY
- Exome Sequencing of Head and Neck Squamous Cell Carcinoma Reveals Inactivating Mutations in NOTCH1
- (2011) N. Agrawal et al. SCIENCE
- The Mutational Landscape of Head and Neck Squamous Cell Carcinoma
- (2011) N. Stransky et al. SCIENCE
- Specific TP53 mutations predict aggressive phenotype in head and neck squamous cell carcinoma: a retrospective archival study
- (2011) Jenni K Peltonen et al. Head and Neck Optical Diagnostics Society
- Phase 1 Trial of Gemcitabine With Bortezomib in Elderly Patients With Advanced Solid Tumors
- (2010) Satya V. Bommakanti et al. AMERICAN JOURNAL OF CLINICAL ONCOLOGY-CANCER CLINICAL TRIALS
- Two-Stage Phase I Dose-Escalation Study of Intratumoral Reovirus Type 3 Dearing and Palliative Radiotherapy in Patients with Advanced Cancers
- (2010) K. J. Harrington et al. CLINICAL CANCER RESEARCH
- A Phase I Study of the Combination of Intravenous Reovirus Type 3 Dearing and Gemcitabine in Patients with Advanced Cancer
- (2010) M. P. Lolkema et al. CLINICAL CANCER RESEARCH
- REO-10: A Phase I Study of Intravenous Reovirus and Docetaxel in Patients with Advanced Cancer
- (2010) C. Comins et al. CLINICAL CANCER RESEARCH
- Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008
- (2010) Jacques Ferlay et al. INTERNATIONAL JOURNAL OF CANCER
- Phase I Trial of Bortezomib and Concurrent External Beam Radiation in Patients With Advanced Solid Malignancies
- (2010) Thomas J. Pugh et al. INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS
- HDAC inhibitor vorinostat enhances the antitumor effect of gefitinib in squamous cell carcinoma of head and neck by modulating ErbB receptor expression and reverting EMT
- (2010) Francesca Bruzzese et al. JOURNAL OF CELLULAR PHYSIOLOGY
- TP53Mutations and Pathologic Complete Response to Neoadjuvant Cisplatin and Fluorouracil Chemotherapy in Resected Oral Cavity Squamous Cell Carcinoma
- (2010) Federica Perrone et al. JOURNAL OF CLINICAL ONCOLOGY
- PS-341 and Histone Deacetylase Inhibitor Synergistically Induce Apoptosis in Head and Neck Squamous Cell Carcinoma Cells
- (2010) J. Kim et al. MOLECULAR CANCER THERAPEUTICS
- A combination treatment with SAHA and ad-p63/p73 shows an enhanced anticancer effect in HNSCC
- (2010) Seon-Hui Shim et al. TUMOR BIOLOGY
- Nuclear factor-kappa B pathway and response in a phase II trial of bortezomib and docetaxel in patients with recurrent and/or metastatic head and neck squamous cell carcinoma
- (2009) C. H. Chung et al. ANNALS OF ONCOLOGY
- Phase I study of bortezomib and cetuximab in patients with solid tumours expressing epidermal growth factor receptor
- (2009) A Z Dudek et al. BRITISH JOURNAL OF CANCER
- Proteasome Inhibition Blocks Ligand-Induced Dynamic Processing and Internalization of Epidermal Growth Factor Receptor via Altered Receptor Ubiquitination and Phosphorylation
- (2009) A. H. Kesarwala et al. CANCER RESEARCH
- HDAC inhibitor valproic acid enhances tumor cell kill in adenovirus-HSVtk mediated suicide gene therapy in HNSCC xenograft mouse model
- (2009) Vishal Kothari et al. INTERNATIONAL JOURNAL OF CANCER
- Gastrosplenic Fistula From Hodgkin's Lymphoma
- (2009) Carolyn D. Seib et al. JOURNAL OF CLINICAL ONCOLOGY
- Predictors of Competing Mortality in Advanced Head and Neck Cancer
- (2009) Loren K. Mell et al. JOURNAL OF CLINICAL ONCOLOGY
- The histone deacetylase inhibitor LBH589 inhibits expression of mitotic genes causing G2/M arrest and cell death in head and neck squamous cell carcinoma cell lines
- (2009) Michael B Prystowsky et al. JOURNAL OF PATHOLOGY
- Platinum-Based Chemotherapy plus Cetuximab in Head and Neck Cancer
- (2008) Jan B. Vermorken et al. NEW ENGLAND JOURNAL OF MEDICINE
Find Funding. Review Successful Grants.
Explore over 25,000 new funding opportunities and over 6,000,000 successful grants.
ExploreFind the ideal target journal for your manuscript
Explore over 38,000 international journals covering a vast array of academic fields.
Search